Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAIT engager
- Development stage
- Preclinical
- Lead developer
- Biomunex Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MAIT engagers are a novel class of bispecific, tetravalent immune cell engagers developed by Biomunex Pharmaceuticals using their proprietary BiXAb platform. These agents are designed to specifically target and activate Mucosal Associated Invariant T cells (MAITs) by binding to their unique T cell receptor (TCR) and tethering them to tumor-associated antigens on cancer cells. Unlike traditional CD3-based T-cell engagers, MAIT engagers do not activate regulatory T cells (Tregs) or cause broad CD4 T-cell activation, potentially reducing the risk of cytokine release syndrome (CRS) and immune suppression within the tumor microenvironment. Preclinical data demonstrate potency comparable to CD3 engagers with a superior safety profile and efficacy in solid tumor models, including ovarian cancer.
- Other names
- BiXAb MAIT engager
02
Targets
MAIT TCR (Mucosal-associated invariant T-cell receptor)GPC3 (Glypican-3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on MAIT engager.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAIT engager.